Anthony  Doyle net worth and biography

Anthony Doyle Biography and Net Worth

Anthony Doyle serves as Chief Financial Officer, Senior Vice President of the Company. He joins the Company from Worldwide Clinical Trials Holdings, Inc. (“WCT”), a full service global contract research organization, where he served as Chief Financial Officer since 2014. From 2004 to 2012, Mr. Doyle held a series of increasingly responsible roles at General Electric, moving through financial planning & analysis, controller, audit, tax and commercial finance rotations in the GE Financial Management and Corporate Audit Staff finance and leadership training programs. He then led risk and pricing for GE Healthcare’s $1.2 billion U.S. diagnostic imaging business and served as global program manager for GE Healthcare Solutions, a hospital and healthcare outcomes-based consulting company. From 2012 to 2014, he was CFO of World Book, a Berkshire Hathaway company. Mr. Doyle completed his Bachelor’s degree from Dublin City University (Ireland) and his DESEM from Reims Management School (France). Mr. Doyle also has a Graduate Certificate in Corporate Treasury from Dublin City University.

What is Anthony Doyle's net worth?

The estimated net worth of Anthony Doyle is at least $932,966.54 as of December 15th, 2022. Mr. Doyle owns 163,966 shares of BioCryst Pharmaceuticals stock worth more than $932,967 as of December 10th. This net worth estimate does not reflect any other assets that Mr. Doyle may own. Additionally, Mr. Doyle receives an annual salary of $726,420.00 as CFO at BioCryst Pharmaceuticals. Learn More about Anthony Doyle's net worth.

How old is Anthony Doyle?

Mr. Doyle is currently 43 years old. There are 8 older executives and no younger executives at BioCryst Pharmaceuticals. The oldest executive at BioCryst Pharmaceuticals is Dr. Yarlagadda S. Babu, Chief Discovery Officer, who is 70 years old. Learn More on Anthony Doyle's age.

What is Anthony Doyle's salary?

As the CFO of BioCryst Pharmaceuticals, Inc., Mr. Doyle earns $726,420.00 per year. There are 3 executives that earn more than Mr. Doyle. The highest earning executive at BioCryst Pharmaceuticals is Mr. Jon P. Stonehouse, CEO, President & Executive Director, who commands a salary of $1,150,000.00 per year. Learn More on Anthony Doyle's salary.

How do I contact Anthony Doyle?

The corporate mailing address for Mr. Doyle and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at [email protected]. Learn More on Anthony Doyle's contact information.

Has Anthony Doyle been buying or selling shares of BioCryst Pharmaceuticals?

Anthony Doyle has not been actively trading shares of BioCryst Pharmaceuticals during the past quarter. Most recently, Anthony Doyle sold 5,700 shares of the business's stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $10.90, for a transaction totalling $62,130.00. Following the completion of the sale, the chief financial officer now directly owns 163,966 shares of the company's stock, valued at $1,787,229.40. Learn More on Anthony Doyle's trading history.

Who are BioCryst Pharmaceuticals' active insiders?

BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Nancy Hutson (Director), Vincent Milano (Director), William Sheridan (Insider), and Jon Stonehouse (CEO). Learn More on BioCryst Pharmaceuticals' active insiders.

Are insiders buying or selling shares of BioCryst Pharmaceuticals?

During the last twelve months, insiders at the biotechnology company sold shares 6 times. They sold a total of 127,370 shares worth more than $1,324,621.75. The most recent insider tranaction occured on June, 15th when Director Machelle Sanders sold 4,000 shares worth more than $31,920.00. Insiders at BioCryst Pharmaceuticals own 4.4% of the company. Learn More about insider trades at BioCryst Pharmaceuticals.

Information on this page was last updated on 6/15/2023.

Anthony Doyle Insider Trading History at BioCryst Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2022Sell5,700$10.90$62,130.00163,966View SEC Filing Icon  
11/23/2021Buy35,258$12.48$440,019.84View SEC Filing Icon  
8/11/2020Buy54,000$4.08$220,320.0054,000View SEC Filing Icon  
See Full Table

Anthony Doyle Buying and Selling Activity at BioCryst Pharmaceuticals

This chart shows Anthony Doyle's buying and selling at BioCryst Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals logo
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $5.69
Low: $5.59
High: $5.82

50 Day Range

MA: $5.73
Low: $4.98
High: $6.77

2 Week Range

Now: $5.69
Low: $4.82
High: $12.07


5,120,367 shs

Average Volume

3,669,082 shs

Market Capitalization

$1.17 billion

P/E Ratio


Dividend Yield